MFN News Items | Nanologica

The Nomination Committee Proposes Election of Mark Quick and Erik Haeffler as New Board Members of Nanologica AB (publ)

10 March, 2026

The nomination committee of Nanologica proposes to the Annual General Meeting on May 21 that Mark Quick and Erik Haeffler be elected as new members of the board of directors of Nanologica AB. Furthermore, Thomas Eldered is proposed as new chairman of the board. Mark Quick works as a Partner at Flerie AB having previously worked at Recipharm where he was Head of Corporate Development leading the M&A activities. Prior to that he held positions

Valberedningen föreslår nyval av Mark Quick och Erik Haeffler som styrelseledamöter i Nanologica AB (publ)

10 March, 2026

Valberedningen i Nanologica föreslår inför årsstämman den 21 maj att Mark Quick och Erik Haeffler väljs som nya styrelseledamöter i Nanologica AB. Vidare föreslås Thomas Eldered som ny ordförande. Mark Quick arbetar som partner på Flerie AB och kommer från en tidigare roll på Recipharm där han var chef för företagsutveckling och ledde M&A-aktiviteterna. Innan dess har Mark Quick innehaft positioner inom ICI, Medeva, Celltech och UCB i olika roller inom affärsutveckling och leveranskedja. Han

Nanologica offentliggör utfallet i riktade nyemissioner

10 March, 2026

Nanologica AB (publ) (“Nanologica” eller “Bolaget”) offentliggör härmed utfallet av de två riktade nyemissioner som beslutades av styrelsen den 30 januari 2026 och godkändes av den extra bolagsstämman den 4 mars 2026. Emissionerna omfattade totalt 34 203 780 aktier. Samtliga aktier har tecknats och tilldelats i enlighet med emissionsbesluten. Ardena Sweden AB har tecknat och tilldelats samtliga 21 453 780 aktier i kvittningsemissionen. Teckningskursen uppgick till 0,40 SEK per aktie, motsvarande ett totalt teckningsbelopp om

Nanologica Announces Outcome of Directed Share Issues

10 March, 2026

Nanologica AB (publ) (”Nanologica” or ”the Company”) hereby announces the outcome of the two directed issues of shares resolved by the board of directors on 30 January 2026 and approved by the extraordinary general meeting on 4 March 2026. The directed issues comprised a total of 34,203,780 shares. All shares have been subscribed for and allotted in accordance with the resolutions. Ardena Sweden AB has subscribed for and been allotted all 21,453,780 shares in the

Nanologica Publishes Information Document Regarding Directed Share Issues and Rights Issue

6 March, 2026

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION REQUIRES A PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE CONTRAVENES APPLICABLE RULES IN SUCH JURISDICTION OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH

Nanologica offentliggör informationsdokument avseende riktade nyemissioner och företrädesemission

6 March, 2026

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN DISTRIBUTION KRÄVER PROSPEKT, REGISTRERING ELLER ANDRA ÅTGÄRDER UTÖVER DE SOM FÖLJER AV SVENSK RÄTT, ÄR FÖRBJUDEN, ELLER ANNARS STRIDER MOT TILLÄMPLIGA REGLER I SÅDAN JURISDIKTION ELLER INTE KAN SKE UTAN TILLÄMPNING AV UNDANTAG FRÅN SÅDAN ÅTGÄRD. SE AVSNITTET "VIKTIG INFORMATION" I SLUTET

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.